Rani Therapeutics (RANI)
(Delayed Data from NSDQ)
$3.20 USD
+0.38 (13.48%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $3.20 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RANI 3.20 +0.38(13.48%)
Will RANI be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for RANI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RANI
What Makes Rani Therapeutics Holdings, Inc. (RANI) a New Buy Stock
Rani Therapeutics Holdings, Inc. (RANI) Reports Q3 Loss, Lags Revenue Estimates
RANI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Rani Therapeutics Holdings, Inc. (RANI) Is a Great 'Buy the Bottom' Stock Now
Rani Therapeutics Holdings, Inc. (RANI) Reports Q2 Loss, Misses Revenue Estimates
Axsome (AXSM) Hurt by Regulatory Setbacks: Will It Recover?
Other News for RANI
Analysts Offer Insights on Healthcare Companies: Hoth Therapeutics (HOTH), Rewalk Robotics (LFWD) and Rani Therapeutics Holdings (RANI)
Buy Rating Maintained for Rani Therapeutics: A Financial and Risk Analysis Amidst Recent Equity Financing
Rani Therapeutics price target lowered by $4 at H.C. Wainwright, here's why
Analysts Conflicted on These Healthcare Names: Merus (MRUS), Staar Surgical (STAA) and Rani Therapeutics Holdings (RANI)
Analysts Offer Insights on Healthcare Companies: Outset Medical (OM), Rani Therapeutics Holdings (RANI) and Charles River Labs (CRL)